相关临床试验
1
1 进行中
药物批准
3
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
1
100.0%
- CHARM Therapeutics has appointed Dr. Erkut Bahceci as Chief Medical Officer following an $80 million Series B financing to advance its next-generation menin inhibitor for acute myeloid leukemia. - Dr. Bahceci brings over two decades of hematology and oncology experience, having led clinical development programs at major pharmaceutical companies including Takeda, Astellas, and Bristol-Myers Squibb. - The company's lead menin inhibitor, developed using its proprietary DragonFold platform, is designed to overcome resistance mutations and deliver deeper responses for AML patients. - Clinical development is expected to begin in 2026 with first-in-human studies under Dr. Bahceci's leadership.
- Avacta Group plc has appointed David Liebowitz, M.D., Ph.D. as Chief Medical Officer to lead clinical strategy and execution for its targeted cancer therapy pipeline. - Liebowitz brings over 30 years of experience in oncology drug development and has contributed to more than 25 Investigational New Drug applications throughout his career. - The company also appointed Yulii Bogatyrenko as business development advisor to strengthen corporate growth strategy and pipeline advancement. - These appointments come at a pivotal time as Avacta continues to advance its pre|CISION platform for targeted oncology drug delivery.
- Enara Bio has appointed Stacey Davis as Chief Business Officer and Chief Financial Officer, bringing over 25 years of biotech experience to strengthen the company's business development and capital strategy. - Clive Wood, Ph.D., former Global Head of Discovery Research at Boehringer Ingelheim and discoverer of the PD-1: PD-L1/PD-L2 pathway, joins Enara's board as Non-executive Director. - The leadership appointments come as Enara prepares to transition its lead Dark Antigen-targeted T-cell engager assets toward clinical development. - The company's EDAPT platform enables discovery of cancer-specific antigens from previously uncharted genomic 'dark matter' for developing TCR-based immunotherapies against solid tumors.
- Glenmark Therapeutics has launched Polyethylene Glycol 3350 powder (17 grams/capful) as an over-the-counter constipation treatment in the US market, comparable to MiraLAX®. - The company enters a lucrative market segment that generated approximately $555.7 million in annual sales for the period ending February 2025, according to Nielsen® syndicated data. - This strategic product introduction addresses growing demand for alternative suppliers in the constipation treatment category, reinforcing Glenmark's commitment to expanding its OTC healthcare portfolio.
